MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$3,294,163
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Accounts payable
Stock-based compensation
Others
Negative Cash Flow Breakdown
Net loss
Common stock issuance costs
Accrued expenses
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-3,591,304
-3,287,917
-2,455,630
-2,972,410
Depreciation and amortization
5,746
5,428
5,429
5,429
Stock-based compensation
103,193
101,068
109,024
113,754
Issuance of common stock to consultants
-
-
39,050
-
Foreign currency (gain) loss
2,953
7,711
-8,701
-5,691
Prepaid expenses and other current and noncurrent assets
-98,755
-181,777
735,651
-169,996
Accounts payable
189,800
32,525
68,924
-554,020
Accrued expenses
-82,000
218,104
-1,139
60,330
Net cash used in operating activities
-3,278,763
-2,756,726
-2,961,292
-3,171,230
Purchases of property and equipment
15,400
-
-
-
Proceeds from the exercise of warrants
-
-
91
-
Net cash used in investing activities
-15,400
-
-
-
Proceeds from issuance of common stock
500,068
35,098,813
4,213,209
375,378
Common stock issuance costs
2,437,775
474,664
371,730
17,438
Net cash provided by financing activities
-1,937,707
34,624,149
3,841,570
357,940
Change in cash, cash equivalents and restricted cash
-
31,867,423
880,278
-2,813,290
Effect of exchange rate changes on cash, cash equivalents and restricted cash
-695
-348
1,273
3,406
Change in cash, cash equivalents and restricted cash
26,634,510
-
-
-
Cash, cash equivalents and restricted cash-beginning of year
46,507,608
14,640,533
13,758,982
22,890,055
Cash, cash equivalents and restricted cash-end of period
41,275,043
-
-
-
Cash and cash equivalents
41,233,428
-
-
-
Restricted cash
41,615
-
-
-
Total cash, cash equivalents and restricted cash
41,275,043
46,507,608
14,640,533
13,758,982
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
something is missing
$31,867,075
Change in cash, cash
equivalents and restricted...
$26,634,510
(521.35%↑ Y/Y)
Canceled cashflow
$5,232,565
Accounts payable
$189,800
(217.45%↑ Y/Y)
Stock-based compensation
$103,193
(-59.59%↓ Y/Y)
Prepaid expenses and
other current and...
-$98,755
(71.60%↑ Y/Y)
Depreciation and
amortization
$5,746
(-47.08%↓ Y/Y)
Proceeds from issuance of
common stock
$500,068
(8.94%↑ Y/Y)
Net cash used in
operating activities
-$3,278,763
(51.51%↑ Y/Y)
Net cash provided by
financing activities
-$1,937,707
(-539.66%↓ Y/Y)
Net cash used in
investing activities
-$15,400
Effect of exchange rate
changes on cash, cash...
-$695
Canceled cashflow
$397,494
Canceled cashflow
$500,068
Net loss
-$3,591,304
(49.92%↑ Y/Y)
Common stock issuance
costs
$2,437,775
(13227.73%↑ Y/Y)
Purchases of property and
equipment
$15,400
Accrued expenses
-$82,000
(33.70%↑ Y/Y)
Foreign currency (gain)
loss
$2,953
(103.65%↑ Y/Y)
Buy us a coffee
Aprea Therapeutics, Inc. (APRE)
Aprea Therapeutics, Inc. (APRE)